These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27009937)

  • 1. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
    He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
    Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
    Domingo E; Kelly C; Hay J; Sansom O; Maka N; Oien K; Iveson T; Saunders M; Kerr R; Tomlinson I; Edwards J; Harkin A; Nowak M; Koelzer V; Easton A; Boukovinas I; Moustou E; Messaritakis I; Chondrozoumaki M; Karagianni M; Pagès F; Arnoux F; Lautard C; Lovera Y; Boquet I; Catteau A; Galon J; ; Souglakos I; Church DN
    J Clin Oncol; 2024 Jun; 42(18):2207-2218. PubMed ID: 38484206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.
    Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y
    EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of clinical characteristics of mismatch repair status in colorectal cancer: a multicenter retrospective study.
    Mao J; He Y; Chu J; Hu B; Yao Y; Yan Q; Han S
    Int J Colorectal Dis; 2024 Jul; 39(1):100. PubMed ID: 38967814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting.
    Grillo F; Angerilli V; Parente P; Vanoli A; Luchini C; Sciallero S; Puccini A; Bergamo F; Lonardi S; Valeri N; Mastracci L; Fassan M
    Virchows Arch; 2024 Jul; 485(1):131-135. PubMed ID: 38141133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
    Malla SB; Fisher DJ; Domingo E; Blake A; Hassanieh S; Redmond KL; Richman SD; Youdell M; Walker SM; Logan GE; Chatzipli A; Amirkhah R; Humphries MP; Craig SG; McDermott U; Seymour MT; Morton DG; Quirke P; West NP; Salto-Tellez M; Kennedy RD; Johnston PG; Tomlinson I; Koelzer VH; Campo L; Kaplan RS; Longley DB; Lawler M; Maughan TS; Brown LC; Dunne PD;
    Clin Cancer Res; 2021 Jan; 27(1):288-300. PubMed ID: 33028592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence.
    Sinicrope FA; Nelson GD; Saberzadeh-Ardestani B; Segovia DI; Graham RP; Wu C; Hagen CE; Shivji S; Savage P; Buchanan DD; Jenkins MA; Phipps AI; Swallow C; LeMarchand L; Gallinger S; Grant RC; Pai RK; Sinicrope SN; Yan D; Shanmugam K; Conner J; Cyr DP; Kirsch R; Banerjee I; Alberts SR; Shi Q; Pai RK
    Cancer Res Commun; 2024 May; 4(5):1344-1350. PubMed ID: 38709069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and prognoses in younger and older patients with mismatch repair defects colorectal cancer: a retrospective comparative cohort study.
    Zhang J; Li S; Ma P; Zhang J; Cao Y; Liu C; Zhang X; Li Z; Li C; Zhao Y
    J Gastrointest Oncol; 2024 Feb; 15(1):260-270. PubMed ID: 38482236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
    Kelkar SS; Prabhu VS; Zhang J; Ogando YM; Roney K; Verma RP; Miles N; Marth C
    Arch Gynecol Obstet; 2024 Jun; 309(6):2833-2841. PubMed ID: 38634898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms.
    Chen M; Deng S; Cao Y; Wang J; Zou F; Gu J; Mao F; Xue Y; Jiang Z; Cheng D; Huang N; Huang L; Cai K
    Ann Surg Oncol; 2024 Jul; ():. PubMed ID: 38985229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
    Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
    ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
    Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
    J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
    Wu C; Pai RK; Kosiorek H; Banerjee I; Pfeiffer A; Hagen CE; Hartley CP; Graham RP; Sonbol MB; Bekaii-Saab T; Xie H; Sinicrope FA; Patel B; Westerling-Bui T; Shivji S; Conner J; Swallow C; Savage P; Cyr DP; Kirsch R; Pai RK
    Clin Cancer Res; 2024 May; 30(9):1811-1821. PubMed ID: 38421684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
    Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
    Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer.
    Meier C; La Rocca G; Nawrot V; Fißlthaler B; Overby SJ; Hourfar K; Plotz G; Seidl C; Ziegler P; Wild P; Zeuzem S; Brieger J; Jäger E; Battmann A; Brieger A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the management of stage II colon cancer.
    Dotan E; Cohen SJ
    Semin Oncol; 2011 Aug; 38(4):511-20. PubMed ID: 21810510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite Instability in Sporadic Colorectal Malignancy: A Pilot Study from Northern India.
    Chauhan S; Kumar S; Singh P; Husain N; Masood S
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2279-2288. PubMed ID: 34319053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair status and surgical approach in apparent early-stage endometrial cancer.
    Morton R; Webb PM; Na R; Obermair A; Farrell R
    Int J Gynecol Cancer; 2024 Apr; 34(4):535-543. PubMed ID: 38431289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns.
    Fountzilas E; Papadopoulos T; Papadopoulou E; Gouedard C; Kourea HP; Constantoulakis P; Magkou C; Sfakianaki M; Kotoula V; Bantouna D; Raptou G; Saetta AA; Christopoulou G; Hatzibougias D; Michalopoulou-Manoloutsiou E; Siatra E; Eleftheriadis E; Kavoura E; Kaklamanis L; Sourla A; Papaxoinis G; Pavlakis K; Hytiroglou P; Vourlakou C; Arapantoni-Dadioti P; Murray S; Nasioulas G; Timologos G; Fountzilas G; Saridaki Z
    Diagnostics (Basel); 2024 May; 14(11):. PubMed ID: 38893603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creation of a Quality Payment Program Measure for Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal, Endometrial, Gastroesophageal, or Small Bowel Carcinoma.
    Bocsi GT; Laudadio J; Jain R; Eakin SM; Bhalla A; Rosenberg JA; Maratt JK; Kupfer SS; Leiman DA; Cardona DM
    Arch Pathol Lab Med; 2024 Jun; 148(6):728-734. PubMed ID: 37708308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.